Go Deep
Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 24,928 | 0.0 | 0.51 | 0.70 | 161.02 |
| Oct 2026 | 24,954 | 0.0 | 0.48 | 0.70 | 153.44 |
| Oct 2026 | 24,960 | 0.0 | 0.48 | 0.70 | 151.71 |
| Oct 2026 | 24,949 | 0.0 | 0.48 | 0.70 | 153.13 |
| Oct 2026 | 24,948 | 0.0 | 0.48 | 0.70 | 151.33 |
| Oct 2026 | 24,945 | 0.0 | 0.48 | 0.70 | 151.97 |
Aptevo Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -6,356,000.0 | -6,697,000.0 | -5,806,000.0 | -7,549,000.0 |
| EPS | -5.3 | -6.4 | — | -40.1 |
Aptevo Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 3,114,000.0 | — |
| Net Profit | -25,967,000.0 | -24,130,000.0 | -17,411,000.0 | 8,027,000.0 | — |
| EPS | -87.3 | -5,956.6 | -527,606.1 | 729,727.3 | — |
Aptevo Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 27,194,000.0 | 15,591,000.0 | 24,842,000.0 | 34,215,000.0 | — |
| Total Liabilities | 9,813,000.0 | 10,836,000.0 | 12,621,000.0 | 16,241,000.0 | — |
| Total Equity | 17,381,000.0 | 4,755,000.0 | 12,221,000.0 | 17,974,000.0 | — |
Owes vs Owns
Aptevo Therapeutics Inc. owed $0.58 for every $1 it owned in Jun 2026, up from $0.47 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.58× | 0.36× | 0.70× | 0.51× | 0.47× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Aptevo Therapeutics Inc. Assets & Liabilities Breakdown (₹ Cr)
What it owns — Dec 2025
Cash & short-term investments 79.5%Fixed assets (tangible) 15.1%Other assets 5.4%
How it's funded — Dec 2025
Short-term debt 3.2%Long-term debt 13.8%Payables 3.2%Other liabilities 15.8%Shareholders' equity 63.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2.2 | 0.9 | 1.7 | 2.3 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.2 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.4 | 0.5 | 0.6 | 0.7 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.1 | 0.2 | 0.2 | 0.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.1 | 0.1 | 0.0 | 0.2 |
| Long-term debt | 0.4 | 0.5 | 0.5 | 0.1 |
| Payables | 0.1 | 0.1 | 0.4 | 0.3 |
| Other liabilities | 0.4 | 0.4 | 0.3 | 0.9 |
| Shareholders' equity | 1.7 | 0.5 | 1.2 | 1.8 |
| Net tangible assets | 1.7 | 0.5 | 1.2 | 1.8 |
Aptevo Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -25,592,000.0 | -23,785,000.0 | -11,730,000.0 | -21,022,000.0 | — |
| Investing Activities | 0.0 | 0.0 | 0.0 | -29,000.0 | — |
| Financing Activities | 38,497,000.0 | 15,595,000.0 | 5,998,000.0 | -2,616,000.0 | — |